

Special Issue

Pharmacogenomics: Challenges and Future –2nd Edition

Message from the Guest Editor

Over the past years, the growth of pharmacogenomics (PGx) within the medical community has contributed to improving the practice of precision medicine. The genetic make-up influences the interindividual variability of drug responses in terms of dosing, drug efficacy/toxicity, hypersensitivity reactions, drug resistance, and clinical outcome. The discovery of PGx biomarkers may lead to tailored prescriptions, with a major impact on healthcare costs. Until now, FDA recommendations are provided for over 200 drugs in several therapeutic areas, especially for cancer. However, PGx implementation is still limited, and several barriers need to be overcome. For this Special Issue, contributions from both experts and beginners in the PGx field are invited. We welcome reviews and original research articles covering many aspects of PGx, from the discovery of new PGx biomarkers to methodological strategies to increase PGx knowledge and implementation, including the validation of PGx biomarkers for clinical translation. Moreover, studies on ethical, legal, and economic aspects and on the role of epigenetic and non-genetic factors are also welcome.

Guest Editor

Dr. Mariamena Arbitrio

Institute of Biomedical Research and Innovation (IRIB-CNR), Section of Catanzaro, 88100 Catanzaro, Italy

Deadline for manuscript submissions

closed (10 August 2024)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/196693

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Department of Pathology, The University of Alabama at Birmingham,
1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))